"This is the pre-peer reviewed version of the following article Khaleva E, Gridneva Z, Geddes DT, et al. Transforming growth factor beta in human milk and allergic outcomes in children: A systematic review. Clin Exp Allergy. 2019;00:1-13. https://doi.org/10.1111/cea.13409, which has been published in final form at https://onlinelibrary.wiley.com/doi/abs/10.1111/cea.13409. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions."

Transforming growth factor beta in human milk and allergic outcomes in children: a systematic review.

Ekaterina Khaleva1,2,* and Zoya Gridneva2,3,* Donna T. Geddes2,3, Wendy H. Oddy4, Silvia Colicino5, Oleg Blyuss6,7, Robert Boyle2,8,9, John Warner2,8,10, Daniel Munblit2,8,11,12

1University of Southampton, Southampton, SO17 1BJ, UK; 2inVIVO Planetary Health, Research Group of the Worldwide Universities Network, West New York, NJ 07093-9992, USA; 3School of Molecular Sciences, The University of Western Australia, Perth, 6009, WA, Australia; 4Nutritional Epidemiology, Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, 7000, Australia; 5The National Heart and Lung Institute, Imperial College London, SW3 6LR, UK; 6Wolfson Institute of Preventive Medicine, Queen Mary University of London, EC1M 6BQ, UK; 7Department of Applied Mathematics, Lobachevsky State University of Nizhny Novgorod, Nizhny Novgorod, 603022, Russia; 8Department of Paediatrics, Imperial College London, London W2 1NY, UK; 9Centre of Evidence-based Dermatology, University of Nottingham, UK; 10Paediatrics and NIHR Collaboration for Leadership in Applied Health Research and Care for NW London, London, UK; 11Faculty of Pediatrics, I. M. Sechenov First Moscow State Medical University, Moscow 119991, Russia; 12Solov'ev Research and Clinical Center for Neuropsychiatry, Moscow 115419, Russia.

Correspondence: Daniel Munblit, MD, PhD, Department of Paediatrics, Department of Medicine, Imperial College London, London, UK. Phone: +447898257151; Email: daniel.munblit08@imperial.ac.uk

* The first two authors contributed equally to this work.
Funding sources
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The authors declare that Medela AG provided an unrestricted research grant to DT Geddes, from which salaries to DT Geddes and Z. Gridneva were paid. JO. Warner is employed by Imperial College through the National Institute of Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care (CLAHRC) for NW London. The views expressed are those of the author(s) and not necessarily those of the UK National Health Service, the NIHR or the Department of Health. WH. Oddy is employed as a Professorial Research Fellow at the Menzies Institute for Medical Research at the University of Tasmania, Australia. RJ. Boyle is supported by a National Institute for Health Research Biomedical Research Centre (BRC), have received research grant income from Danone in relation to studies of the value of prebiotics in allergy prevention. He has received funding to evaluate Airsonette, a temperature-controlled laminar airflow for asthma, and given paid lectures for these companies. D. Munblit has received consultancy payment from Dairy Goat Co-Operative (NZ) Ltd. and has given paid lectures for Merck Sharp & Dohme (MSD) and Bayer. O. Blyuss acknowledges support from Russia under Grant No. 074-02-2018-330. Other authors do not report any financial interest. The funding sponsors had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Total word count: 4995

Abstract

Background: Human milk (HM) transforming growth factor beta (TGF-β) is critical for inflammation regulation and oral tolerance promotion. Previous reports suggested that variations in HM TGF-β levels are associated with allergic outcomes.

Objective: We undertook a systematic review (PROSPERO 2017 CRD42017069920) to reassess the evidence on the relationships between HM TGF-β and allergic outcomes in children.

Methods: Electronic bibliographic databases (MEDLINE, EMBASE, Cochrane Library) were systematically searched. Two independent reviewers screened reference lists, extracted the data and assessed risk of bias using the National Institute for Clinical Excellence methodological checklist.

Results: A total of 21 studies were identified. Sixteen studies assessed relationships between HM TGF-β and risk of eczema; 14, allergic sensitisation; 9, wheezing/asthma; 6, food allergy; 3, allergic rhinitis/conjunctivitis. Five cohorts (5/18, 28%) reported a protective effect of TGF-β1, while 3 (3/10, 30%) suggested increased risk of allergic outcomes development and 1 (1/10, 10%), a protective effect of TGF-β2 on eczema. Meta-analysis was not possible due to significant heterogeneity in methodology, age of outcome assessment and differing statistical approaches. 71% (15/21) of studies carried a high risk of bias.

Conclusion: In contrast with previous findings we did not find strong evidence of associations between HM TGF-β and allergic outcomes. Differences in studies’ methodology and outcomes do not allow unconditional rejection or acceptance of the hypothesis that HM TGF-β influences the risk of allergy development. Future studies on diverse populations employing standardised methods, accurate phenotyping of outcomes and evaluation of the effect of TGF-β in combination with other HM immune markers, microbiome and oligosaccharides are required.

Key Messages

- Basic science evidence suggests that human milk TGF-β is particularly important for oral tolerance development, with previous reports finding associations between TGF-β and immunological outcomes.
- The evidence does not support previous conclusions with most of the studies finding null associations between human milk TGF-β and allergic outcomes in children. Studies lack methodological standardisation, resulting in high heterogeneity.
Future research should focus on the assessment of multiple immune markers, human milk oligosaccharides and microbiome in relationship with the allergic outcomes, as it is highly likely that a combination, rather than a single factor contributes to potential protective effect. Standardisation of methodology, statistical analysis and outcome definitions should be considered a top priority for the future research to allow for data meta-analysis.

Key words

Human milk; breast milk; colostrum; TGF-β; transforming growth factor-beta; allergic outcomes; allergic diseases; allergic sensitization; atopy; breastfeeding.

Abbreviations used

AR: allergic rhinitis
ARC: allergic rhinoconjunctivitis
AS: atopic sensitization
CI: confidence intervals
CMA: cow’s milk allergy
ELISA: enzyme-linked immunosorbent assay
E: eczema
FA: food allergy
ISAAC: international study of asthma and allergies in childhood questionnaire
MM: mature milk
NICE: national institute for clinical excellence methodological checklists
PRISMA: preferred reporting items for systematic reviews and meta-analyses guidelines
HM: human milk
HMO: human milk oligosaccharides
OR: odds ratio
slgE: specific immunoglobulin E
Introduction

Human milk (HM) is the main source of nutrition during early life, a critical period of metabolic and immune programming. It is well known that HM consists of essential macro- and micronutrients, vitamins, antibodies and many other bioactive factors, essential for the growth and development of a newborn infant and for protection against infections. However, there is conflicting evidence on the protective role of breastfeeding in relation to the development of allergic sensitization and allergic diseases with children bearing the greatest burden of these increasingly prevalent conditions in modern relatively affluent environments.

Transforming growth factor-beta (TGF-β) is a regulatory cytokine possessing pleiotropic functions, and is involved in physiological and pathological processes including embryogenesis, immune regulation and inflammation. Three TGF-β isoforms (TGF-β1, 2 and 3) are present in HM with TGF-β2 being a predominant type. TGF-β concentration varies considerably throughout lactation, with highest levels detected in colostrum followed by a rapid decline by 4-6 weeks of life and a continuing decline by 3 and 6 months postpartum. There has been an increasing interest in the role of HM TGF-β as a key immunoregulatory factor that promotes IgA production, assists with mucosal repair in the neonatal gastrointestinal tract, acts as a co-factor helping in the generation of immune regulatory immune responses and influences the neonatal gut microbiome. To date, the most comprehensive review of human studies was conducted a decade ago by Oddy and Rosales, reporting an association between...
TGF-β levels in HM and reduced risk of immunological outcomes in children in two-thirds of the studies. The authors suggested that presence of HM TGF-β may play an important role in gut immunity functioning and maturation, leading to the subsequent promotion of oral tolerance, thus reducing the risk of allergy development. High heterogeneity between the studies was highlighted, with maternal atopic status or dietary intervention during pregnancy and/or lactation suggested as the main reason.

Despite suggested immunological benefits, the role of TGF-β in allergy prevention remains controversial. Discrepant findings may be partially related to the differences in milk collection methodology, sample storage and differences in laboratory approaches. In addition, studies employed different criteria for allergic predisposition of infants, definition of outcome, method of outcome assessment, environmental influence and ethnicity.

The importance of the links between HM composition and allergic disease development has received significant attention recently and objective assessment of existing evidence is timely. The aim of this systematic review is to summarise current knowledge on associations between HM TGF-β and atopy/allergy development.
Methods

This systematic review is reported in accordance with the recommendations set forth by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Methods were published apriori (PROSPERO 2017 CRD42017069920, available from: http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42017069920) on the 6th of July 2017.

Search strategy

An extensive electronic search of MEDLINE, EMBASE and Cochrane Library was performed on the 7th June 2017, using both free text and MESH terms. The search strategies are provided as supplementary material (Table S1). At a screening stage, further studies were traced through cross-checking of reference lists from identified relevant papers.

The relationships between TGF-β concentrations in HM (including colostrum, transitional milk, mature milk) and allergic diseases were studied. The primary outcome variables included atopic dermatitis/eczema, food allergy, asthma, allergic rhinitis, allergic conjunctivitis, allergic sensitization (skin prick test (SPT) and/or specific immunoglobulin E (sIgE) measurement) and serum immunoglobulin concentrations in infants and children.

Eligibility criteria and selection of articles

Studies of all designs were included if the following criteria were met: 1) Reported original data; 2) Clinical study of mother–infant dyads; 3) The study had an epidemiological design: observational studies, i.e. pregnancy cohort study, birth cohort study, human prospective study or randomized controlled trial, during pregnancy or lactation and interventional studies; 4) Included a quantitative assessment of TGF-β in HM; and 5) Investigated associations between HM TGF-β and at least one allergic disease or allergic
sensitization in the child. We excluded reviews, conference abstracts, editorials, letters to the editor, case reports and/or case series.

All included papers were transferred into EndNote reference manager. To reduce potential selection bias two independent investigators (EK and ZG) reviewed all titles and abstracts identified by the search for inclusion. Then EK and ZG independently reviewed full texts of all publications selected for data extraction. Any disagreements were resolved through discussion involving an additional reviewer (DM) and other co-authors if needed, until consensus was reached.

**Data extraction**

The data from each study were extracted in duplicate, tabulated, and included author and year of publication, descriptive information concerning the study design, country and setting, baseline characteristics of the study population, methodology of milk sampling, timing of sample collection, method of assessment of TGF-β concentration, outcome definition, age of outcome assessment, details on statistical analysis and overall TGF-β association with health outcome.

**Quality assessment**

The risk of bias was assessed in duplicate (EK and ZG) using the National Institute for Clinical Excellence (NICE) methodological checklist for cohort studies and a final score was obtained by consensus.
Results

Synthesis

Based on the search strategy, a total of 353 titles were identified and 215 relevant abstracts were screened for eligibility (FIG.1). Of these, 26 met the inclusion criteria and were eligible for full-text assessment with 21 papers (reporting results from 20 study populations) included in our systematic review. One cohort study generated 2 publications and the results were summarised according to the study population, rather than by publication. Five studies were excluded as they did not assess any of the identified outcomes: 1 examined the effect of probiotic administration on the risk of eczema development and allergic sensitization only, without reporting the results on association with HM TGF-β, 2 studies investigated TGF-β in isolation from any allergic outcomes, 2 studies assessed association between TGF-β and immunological but not allergic outcomes in infants. Due to a limited number of studies reporting immunological outcomes, the scope of this systematic review is limited to allergic outcomes. However, as our initial search included search terms relevant for immunological outcomes, these are presented in a separate subsection.
Description of the studies

Twenty-one studies included in this systematic review have been published between 1999 and 2017 and can be grouped into 2 main categories in accordance with the design: (a) interventional and (b) observational (Table I). All included interventional studies administered either single or multiple strains of probiotics for various durations during pregnancy and/or lactation with exception of 1 study, which administered either formula or pasteurized HM. However, the analyses of interventional studies were undertaken within the studies without assessing the association between intervention and allergic outcomes in children. Ten studies measured TGF-β.
assessed all 3 TGF-β isoforms. 

**Participants characteristics**

Study populations included participants from 15 countries, with most research conducted in Scandinavia: 7 studies in Finland, 6, 12, 29, 31, 37, 39, 40 and 3 in Sweden, 10, 21, 32; 3 in USA, 24, 25, 34, 36; 2 in Italy, 35, 38; and 1 in Australia, Denmark, Estonia, France, Germany, New Zealand, Norway, Russia, Switzerland, The Netherlands and UK.

Sample size ranged from 22 to 610 participants while the maximum number of HM samples reached 685. Most of the studies followed children up to the age of 24 months, the maximum age of follow-up was 72 months. Thirty-five percent of cohorts recruited participants at high risk of allergy development (Table I).

**Stage of lactation**

Colostrum was collected within 0–4 days, transitional milk (TM) 5-14 days, and mature milk (MM) between 15 days and 6 months postpartum. Eight cohorts measured TGF-β levels in paired colostrum and MM samples. Of the remaining cohorts, 3 assessed TGF-β levels in colostrum; 1 in TM; 2 in TM and MM and 7 in MM. 

**Methodology of human milk samples collection and storage**

The time of sample collection (time of the day, pre- or post-breastfeed) differed between the studies. Approaches to the sample collection varied with following sampling procedures reported: at the beginning of breastfeed, during breastfeed (from the contra-lateral breast), at the end of breastfeed; 2 hours after the previous breastfeed as a full breast expression or first 2 ounces; pooled samples from 2...
breastfeeds if milk volume was low. Collection of the samples throughout the day also varied, with 4 studies reporting morning collections and 16 not specifying the time. In 3 cohorts HM was collected using electric breast pump while others used manual expression or collected the drip from contra-lateral breast during a breastfeeding session.

Upon collection the samples were either immediately frozen or maintained at room temperature from 30 min up to 12 hours until transported to the laboratory, with most of the studies not fully specifying the storage/transit conditions. Identified differences in HM samples preparation methodology included: centrifugation of the samples before or after freezing and differences in acid treatment of the samples.

**Measurement of TGF-β in human milk**

Sixteen of 21 studies used enzyme-linked immunosorbent assay (ELISA) to quantify TGF-β levels in HM. Other techniques included: immunoassay, multiplex assay, custom-made multiplex assays, electro-chemiluminescence and quantikine immunoassay. There was a considerable heterogeneity in reported TGF-β concentrations, which made quantitative synthesis (meta-analysis) not possible. Lower levels of detection for TGF-β1 differed among the studies varying from 7 pg/ml to 30 pg/ml and 60 pg/ml using ELISA, while detection levels for TGF-β2 were 60 pg/ml using both ELISA and immunoassay.

**Statistical analyses**

Studies included into this systematic review can be classified based on statistical methods used to address the research aim. Statistical approaches included: (a) univariate methods such as tests for groups comparison and univariate analysis of the variance (ANOVA); (b) classical multivariate regression to assess the association between risk factors and health outcome(s) adjusting for a number of confounders;
and (c) more advanced techniques such as least absolute shrinkage and selection operator (LASSO), principal components analysis (PCA) and causal mediation. Most of the studies performed univariate analysis with 15 studies carrying out only ANOVA and/or tests for group comparison such as t-test, chi-square test, Fisher’s exact test and Mann-Whitney U-test. ANOVA was performed in 6 studies to assess time effect, treatment effect and/or the interaction effect on risk factors among groups. Ten studies performed multivariate logistic regression to estimate the association between risk factors and health outcome after adjusting for potential confounding factors, whilst 3 studies used more advance methods with 2 of them reporting detailed information on sensitivity analysis (Table SII). Eighteen studies did not report sample size power calculation, and none provided information on proportion of missing values among variables and methods used to handle missing values.

Some studies reported ‘trends’, not supported by the statistical analysis results ($P$ - values > 0.05) \cite{10, 21, 29} and only 3 studies \cite{24, 25, 34} accounted for multiple comparisons. Half of the studies \cite{10, 11, 13, 24, 25, 33-37} adjusted for potential confounders, including age, delivery mode, atopic status, length of breastfeeding, use of probiotics, site of collection, HM collection time, total storage time until analysis, introduction of food during the first year of life, paternal history of allergic diseases and presence of older siblings (Table SII).

**Allergic health outcomes measured**

Health outcomes were defined by clinical diagnosis \cite{6, 10-13, 21, 29-32, 34, 38, 39}, parental report \cite{24, 35, 36, 41} and questionnaires with further clinical evaluation by the medical doctor \cite{33, 37, 40} or based on well-validated instruments, such as “The International Study of Asthma and Allergies in Childhood” (ISAAC) study questionnaire \cite{25}, Hanifin and Rajka criteria \cite{10, 29, 33} and UK Working party criteria \cite{11-13, 30} for eczema. A single study obtained information on eczema diagnosis using both questionnaires with further evaluation by medical doctor, while wheezing was reported by parents \cite{41}.
Among health outcomes measured in this review, 16 (80%) population studies assessed the association between TGF-β concentration and risk of eczema, 9 (45%) asthma and/or wheezing, 6 (30%) food allergy development, 3 (15%) allergic rhinoconjunctivitis and 14 (70%) allergic sensitisation (Tables I, SIII).
<table>
<thead>
<tr>
<th>Reference</th>
<th>N of participants/milk samples</th>
<th>Country</th>
<th>Population</th>
<th>TGF-β assessed and method used</th>
<th>Timing of sample collection</th>
<th>Age at outcome (months)</th>
<th>Health outcomes reported (method of assessment)</th>
<th>Overall effect*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Interventional studies</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rautava 2002</td>
<td>31/62</td>
<td>Finland</td>
<td>High risk</td>
<td>TGF-β1,2 (ELISA)</td>
<td>MM (3mo)</td>
<td>24</td>
<td>E, CMA (clinical history, DBPC, SPT), AS (SPT)</td>
<td>NS</td>
</tr>
<tr>
<td>Bottcher 2008</td>
<td>109/109</td>
<td>Sweden</td>
<td>High risk</td>
<td>TGF-β1,2 (ELISA)</td>
<td>C (3d) MM (1mo)</td>
<td>24</td>
<td>E (Hannifin and Rajka criteria), AS (SPT and/or sIgE)</td>
<td>(AS)</td>
</tr>
<tr>
<td>Huurre 2008</td>
<td>140/NR</td>
<td>Finland</td>
<td>High risk</td>
<td>TGF-β1,2 (ELISA)</td>
<td>C (0d) MM (1, 3mo)</td>
<td>24</td>
<td>E (UK Working party criteria), AS (SPT)</td>
<td>NS</td>
</tr>
<tr>
<td>Prescott 2008</td>
<td>105/105</td>
<td>New Zealand</td>
<td>High risk</td>
<td>TGF-β1 (ELISA)</td>
<td>C (3-7d) MM (1, 3mo)</td>
<td>12</td>
<td>AS (SPT)</td>
<td>NS</td>
</tr>
<tr>
<td>Kuitunen 2012</td>
<td>NR/278</td>
<td>Finland</td>
<td>High risk</td>
<td>TGF-β2 (Immunoassay)</td>
<td>C (0-3d) MM (3mo)</td>
<td>60*</td>
<td>FA (OFC); E (UK Working party criteria); A, AR (DD) -*</td>
<td>(E, AD)</td>
</tr>
<tr>
<td>Ismail 2013</td>
<td>79/79</td>
<td>Australia</td>
<td>High risk</td>
<td>TGF-β1 (ELISA)</td>
<td>TM (7d) MM (28d)</td>
<td>12</td>
<td>E (UK Working party criteria), AS (SPT), IgE-associated E (positive SPT)</td>
<td>NS</td>
</tr>
<tr>
<td>Simpson 2016</td>
<td>259/259</td>
<td>Norway</td>
<td>Normal risk</td>
<td>TGF-β1-3 (Multiplex assay)</td>
<td>TM (10d) MM (3mo)</td>
<td>24</td>
<td>E (UK Working party criteria), AS (SPT and/or sIgE)</td>
<td>NS</td>
</tr>
<tr>
<td><strong>Observational studies</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kalliomaki 1999</td>
<td>47/43*</td>
<td>Finland</td>
<td>Normal risk</td>
<td>TGF-β1,2 (ELISA)</td>
<td>C (0d) MM (3mo)</td>
<td>12</td>
<td>E (Hanifin and Rajka criteria)</td>
<td>+ (E)</td>
</tr>
<tr>
<td>Saarinen 1999</td>
<td>325/NR</td>
<td>Finland</td>
<td>Normal risk</td>
<td>TGF-β1 (ELISA)</td>
<td>C (1-4d) MM (3mo)</td>
<td>3-13</td>
<td>CMA (Typical symptoms, SPT, sIgE), AS (positive SPT or sIgE)</td>
<td>+ (AS)</td>
</tr>
<tr>
<td>Bottcher 2003</td>
<td>53/53</td>
<td>Sweden</td>
<td>Normal risk</td>
<td>TGF-β1,2 (ELISA)</td>
<td>C (0-4d) MM (1mo)</td>
<td>24</td>
<td>AS (SPT); A,E,ARC (DD) *</td>
<td>NS</td>
</tr>
<tr>
<td>Oddy 2003</td>
<td>243/142*</td>
<td>USA</td>
<td>Normal risk</td>
<td>TGF-β1 (ELISA)</td>
<td>TM (14d)</td>
<td>12</td>
<td>W (Parental-reported)</td>
<td>+ (W)</td>
</tr>
<tr>
<td>Savilahti 2005</td>
<td>228/227*</td>
<td>Finland</td>
<td>Normal risk</td>
<td>TGF-β1,2 (Quantikine Immunoassay)</td>
<td>C (1-4d) MM (3mo)</td>
<td>48</td>
<td>CMA, E, A, AR, AC (questionnaire, paediatrician evaluation), AS (SPT, sIgE)</td>
<td>NS</td>
</tr>
<tr>
<td>Rigotti 2006</td>
<td>22/22</td>
<td>Italy</td>
<td>Normal risk</td>
<td>TGF-β1 (ELISA)</td>
<td>C (3d) MM (1mo)</td>
<td>6</td>
<td>E (paediatrician evaluation)</td>
<td>NS</td>
</tr>
<tr>
<td>Snijders 2006</td>
<td>315/307*</td>
<td>The Netherlands</td>
<td>Normal risk</td>
<td>TGF-β1 (ELISA)</td>
<td>MM (1mo)</td>
<td>24**</td>
<td>E (ISAAC questionnaire, UK Working party criteria), W (Parental-reported), AS (sIgE)</td>
<td>NS</td>
</tr>
<tr>
<td>Tomicic 2010</td>
<td>99/99</td>
<td>Estonia, Sweden</td>
<td>Normal risk</td>
<td>TGF-β1,2 (ELISA)</td>
<td>C (0-4d) MM (1mo)</td>
<td>24</td>
<td>AS (SPT and/or sIgE); E (DD)</td>
<td>NS</td>
</tr>
</tbody>
</table>
Table I. Characteristics of the included studies A, asthma; AD, allergic diseases (cumulative outcome); AR, allergic rhinitis; ARC, allergic rhinoconjunctivitis; AS, allergic sensitization; C, colostrum (0-4 days) CMA, cow’s milk allergy; D, days; DBPCFC, double-blind placebo-controlled food challenge; DD, doctor diagnosis; E, eczema; ELISA, enzyme-linked immunosorbent assay; FA, food allergy; ISAAC, International Study of Asthma and Allergies in Childhood; MM, mature milk (2 weeks and later); MO, months; NR, not reported; OFC, oral food challenge; SPT, skin prick test; sIgE, specific IgE levels; TGF-β, transforming growth factor-beta; TM, transitional milk (5-14 days); W, wheezing.

<table>
<thead>
<tr>
<th>Study</th>
<th>Sample Size</th>
<th>Country</th>
<th>Risk Level</th>
<th>Milk Composition</th>
<th>Biomarker</th>
<th>Study Duration</th>
<th>Outcome Assessment</th>
<th>Effect Size</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Soto-Ramirez 2012²⁵</td>
<td>178/115</td>
<td>USA</td>
<td>Normal risk</td>
<td>TGF-β1 (ELISA)</td>
<td>MM (21d)</td>
<td>12</td>
<td>Scratching (questionnaires); asthma-like symptoms (ISAAC questionnaire)</td>
<td>+ (W)</td>
<td></td>
</tr>
<tr>
<td>Joseph 2014³⁴</td>
<td>304/304</td>
<td>USA</td>
<td>Normal risk</td>
<td>TGF-β1 (ELISA)</td>
<td>MM (1mo)</td>
<td>36</td>
<td>FA (DD), AS (SPT, slgE)</td>
<td>+ (AS)</td>
<td></td>
</tr>
<tr>
<td>Orivuori 2014³⁷</td>
<td>610/610</td>
<td>Finland, France, Germany, Switzerland</td>
<td>Normal risk</td>
<td>TGF-β1 (ELISA)</td>
<td>MM (2mo)</td>
<td>72 ***</td>
<td>E and A (questionnaires, DD), AS (slgE)</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>Jepsen 2016³³</td>
<td>223/223</td>
<td>Denmark</td>
<td>High risk</td>
<td>TGF-β1 (custom-made Multiplex Assay)</td>
<td>MM (1mo)</td>
<td>36</td>
<td>E (Hanifin and Rajka criteria), W (daily diaries, DD)</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>Munblit 2017³⁸</td>
<td>398/315</td>
<td>UK, Italy, Russia</td>
<td>Normal risk</td>
<td>TGF-β1-3 (Electro-chemiluminescence)</td>
<td>C (0-6d) MM (1mo)</td>
<td>6</td>
<td>E, FA, W (Parental-reported), AS (SPT)</td>
<td>– (E)</td>
<td></td>
</tr>
</tbody>
</table>

Table I. Characteristics of the included studies A, asthma; AD, allergic diseases (cumulative outcome); AR, allergic rhinitis; ARC, allergic rhinoconjunctivitis; AS, allergic sensitization; C, colostrum (0-4 days) CMA, cow’s milk allergy; D, days; DBPCFC, double-blind placebo-controlled food challenge; DD, doctor diagnosis; E, eczema; ELISA, enzyme-linked immunosorbent assay; FA, food allergy; ISAAC, International Study of Asthma and Allergies in Childhood; MM, mature milk (2 weeks and later); MO, months; NR, not reported; OFC, oral food challenge; SPT, skin prick test; sIgE, specific IgE levels; TGF-β, transforming growth factor-beta; TM, transitional milk (5-14 days); W, wheezing.

* SPT with common allergens and/or slgE were assessed and associations between TGF-β and eczema reported up to 2 years; ** Eczema was evaluated up to 12 months; *** Eczema was evaluated up to 4 years. * overall effect of TGF-β1-3; "NS" - no significant effect; "+" - protective effect, "–" - higher risk of development of any reported allergic disease and/or allergic sensitization. * Children at high risk of allergy development were identified based on allergic history of mothers and/or family history. * Number of analysed milk samples for TGF-β concentration unless not reported. * Some allergic outcomes were combined for the purpose of statistical analyses.
TGF-β and development of allergic diseases

Overall, 60% of study populations in the review (12/20) showed no associations with HM TGF-β, 5/20 (25%) – protective effect and 3/20 (15%) – higher risk of allergy development (Tables I and SIII; FIG.2).

TGF-β1 showed either no or some protective effect (5/18, 28%) on infant allergic outcomes, while conflicting results coming from TGF-β2 studies, with 3 studies (3/10, 30%) reporting high risk of allergy development and 1 (1/10, 10%) – protective effect of TGF-β2 (FIG.3). TGF-β3 showed no associations with allergy development or allergic sensitisation 13,35. Five out of 15 individual health outcomes assessed at children below 2 years of age were associated with TGF-β in HM. Out of 30 individual health outcomes assessed at 2 years of age and beyond, only 3 were associated with the levels of TGF-β in HM (FIG.2).

![FIG.2. Matrix of associations between TGF-β (cumulatively isoforms 1,2 and 3) in human milk and allergic outcomes at different age of outcome assessment. Horizontal lines indicate age of outcome assessment and vertical lines indicate allergic outcomes. Blue circle size indicates the total number of studies representing the matrix point and internal, smaller circles, indicate the number of studies showing positive (green circle)/negative (red circle) association between TGF-β and given allergic outcome, if available. Y.O. – years old, MO. – months.]
FIG. 3. Summary of associations between different isoforms of transforming growth factor beta in human milk and allergic outcomes in children. Colored boxes show significant positive (green) or negative (red) association between TGF-β and particular allergic outcome. * Allergic outcomes in this study were combined for the purpose of statistical analyses.

<table>
<thead>
<tr>
<th>Study</th>
<th>Eczema</th>
<th>Food allergy</th>
<th>Asthma/wheezing</th>
<th>Allergic rhinitis and/or conjunctivitis</th>
<th>Atopic sensitization</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Interventional studies</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rautava et al., 2002</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bottcher et al., 2008</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Huurre et al., 2008</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prescott et al., 2008</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kuitunen et al., 2012 *</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TGF-β2</td>
</tr>
<tr>
<td>Ismail et al., 2013</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Simpson et al., 2016</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Observational studies</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kalliomaki et al., 1999</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Saarinen et al., 1999</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bottcher et al., 2003 *</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TGF-β1</td>
</tr>
<tr>
<td>Oddy et al., 2003</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Savilahti et al., 2005</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rigotti et al., 2006</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Snijders et al., 2006</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tomicic et al., 2010</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Soto-Ramirez et al., 2012, 2016</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TGF-β1</td>
</tr>
<tr>
<td>Joseph et al., 2014</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Orivuori et al., 2014</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jepsen et al., 2016</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Munblit et al., 2017</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TGF-β2</td>
</tr>
</tbody>
</table>

**TGF-β and eczema**

No consistent association was found between HM TGF-β and development of eczema. Among 15 studies, only 2 reported higher risk of eczema development in children exposed to HM with higher TGF-β2 levels. According to Munblit et al., infants receiving higher levels of mature
milk TGF-β2 were at higher risk (OR, 1.04; 95% CI, 1.01-1.06) of eczema development at 6 months 35.

Notably, Kuitunen et al. reported no association between TGF-β2 in colostrum and eczema, but higher TGF-β2 concentration in mature milk was associated with eczema at 2 years of life 12. For TGF-β1, Kalliomaki et al. found higher concentrations in colostrum of mothers of infants with post-weaning onset of eczema compared with those with no and pre-weaning onset of disease 6.

**TGF-β and food allergy**

No association between TGF-β in HM and development of food allergy was reported 31, 34, 35, 39, 40, with an exception of Saarinen et al. study, as authors reported concentration of TGF-β1 in colostrum of mothers of infants with non IgE-mediated cow’s milk allergy was significantly higher (mean 1162; 95% CI 881-1531) pg/ml) than in IgE-mediated cow’s milk allergy (589; 413-840) and healthy individuals (807; 677-963 pg/ml) 39.

**TGF-β and allergic sensitization**

Among 20 cohorts 10, 11, 13, 21, 29-32, 34, 35, 37, 39-41 14 investigated relationship between HM TGF-β and allergic sensitization with only two reporting protective effect and one associated with high risk. Bottcher et al. found lower levels of TGF-β2 (<701 pg/ml) in colostrum of mothers of non-sensitized children at 24 months of age (OR, 0.3; 95% CI, 0.1-0.9), although higher levels (>1400 pg/ml) were not associated with an increased risk of sensitization at 6 months of age (OR, 5.0; 95% CI, 0.9-27; P = .06) 10. Saarinen et al. 39 reported weak negative correlation between the concentration of colostrum TGF-β1 and SPT diameter to cow’s milk (r = -0.23; P = 0.02), β-lactoglobulin (r = -0.35, P = .01) and stimulation index to α-casein (r = -0.28, P = .04) measured in infants with cow’s milk allergy at the time of the challenge. In the study of Joseph et al., among non-atopic mothers HM TGF-β1 concentrations were lower for those infants classified as allergen-specific sIgE (1347, 1134-1600 vs. 1651, 1427-1910 pg/ml respectively, P = .047) but among atopic mothers concentrations for these infants were higher (2161, 1868-2499 vs. 1525, 1347-
1726 pg/ml, $P = .001$), with no significant difference in concentration when stratified by positive SPT.

Orivuori et al. reported no consistent results at 4 and 6 years, however, at 6 years adjusted logistic regression models for IgE cut-off of 3.5 kU/l, but not for 0.35 and 0.7 kU/l, showed a significant difference (aOR, 95% CI: Q1, 0.40, 0.18-0.90, $P < 0.05$; Q2, 0.26, 0.11-0.61, $P < 0.01$).

**TGF-β and asthma/recurrent wheezing**

Seven studies investigated associations between HM TGF-β and either asthma or recurrent wheezing. Most of the studies reported no significant findings with only 2 detecting a protective effect of TGF-β1. In adjusted analyses, Soto-Ramirez et al. found that infants exposed to higher levels of TGF-β1 in mature HM had a lower risk of development of asthma-like symptoms at 6 and 12 months (RR = 0.31 (0.13-0.76) and 0.26 ($P = 0.01$) respectively). Similarly, Oddy et al. found a smaller percentage of wheeze in infants that received a higher dose of TGF-β1 through transitional HM ($P = 0.02$).

**TGF-β and allergic rhinitis/allergic rhinoconjunctivitis**

The association between HM TGF-β levels and allergic rhinitis and/or allergic rhinoconjunctivitis was assessed in one cohort only, with no significant associations found.

**TGF-β and immunological outcomes**

Although our systematic review is focused on allergic outcomes, the initial search included search terms for immunological outcomes, so we provide an overview of the existing studies approaching this topic. Ogawa et al. studied associations between TGF-β1 and TGF-β2 in colostrum of healthy mothers and serum IgA in newborns during the first month of life. Notably, an increase of serum IgA in infants from birth to 1 month of life correlated with levels of both TGF-β1 ($r = 0.38$, $P = .005$) and TGF-β2 ($r = 0.45$, $P < 0.001$), while increase of IgM marginally correlated only with TGF-β2 ($r = 0.28$, $P = 0.04$) suggesting...
that colostral TGF-β may serve as the stimulus for IgA production in newborn infants. In line with this
notion, Saarinen et al. found a positive correlation between TGF-β1 in colostrum and both, IgA antibodies
to β-lactoglobulin (r = 0.204, P = 0.04) and IgG antibodies to α-casein (r = 0.237, P = 0.02) in infants
prone to CMA. Moreover, the size of SPT to CM (r = -0.228, P = 0.02) was negatively associated with
the level of TGF-β1, indicating that TGF-β1 may inhibit IgE-mediated reactions to CM. Comparatively,
TGF-β2 concentration in colostrum has been reported to associate with specific IgA responses to dietary
antigens at 3 months of age (P = 0.048). In contrast, Prokesova et al. investigated changes in the immune
system of children genetically predisposed to allergic diseases reporting no significant differences in
concentrations of TGF-β in colostrum and mature HM of allergic mothers compared with non-allergic
mothers. Although differences in concentrations of serum cytokines (IL-4, IL-10, IFN-γ) between the
groups of healthy and high risk infants were reported, no analysis was conducted to test for associations
between concentrations of HM TGF-β and these immunological outcomes. The latter study, while
reporting TGF-β concentrations in mature HM beyond the first month of lactation, did not differentiate
between TGF-β isoforms. Difference in methodology, study design and immunological outcomes
assessed does not allow for an appropriate analysis of these data.

**Risk of bias**

All the studies included in this systematic review were evaluated for their quality, with most being of a
medium quality (FIG.3). High risk of bias was detected in 15 studies (71%). The main issues identified
were attrition, selection and detection bias, including lack of adjustment for potential confounders and the
use of self-reported questionnaires as a tool for allergic outcomes assessment.

It is worth noting that asthma diagnosis at the age below 3 years was considered an unreliable outcome as
most children with “early wheeze” do not develop subsequent asthma. We also considered any allergic
outcome based on non-validated questionnaires without following clinical examination by doctor as a
high risk of bias. We acknowledged any adjustments for known confounders performed by the authors,
but there is no clear guidance which adjustments are imperative. Attrition bias was calculated for all participants as it is not always clear if the same participants provided samples and completed the follow-up; high attrition bias was considered as $\leq 75\%$. 
Fig. 3 Risk of bias in studies assessing association between TGF-β concentration in human milk and allergic outcomes using the National Institute for Clinical Excellence methodological checklist. ‘+', green, low risk of bias; ‘-', red, high risk of bias; ‘?', yellow, unclear risk of bias.
Discussion

In this systematic review, we summarised findings of 21 studies from 20 cohorts of associations between HM TGF-β and allergic outcomes in infancy and childhood. Data from included studies showed no strong association between any isoform of TGF-β in HM and atopy/allergy development. Twelve new studies were identified since the last systematic review, but evidence remains limited, due to high heterogeneity between studies, which makes any quantitative synthesis impossible. We used robust methods to search and synthesize evidence, provided critical analysis, identified several key strengths and limitations in the current literature and highlighted the unmet needs. In this paper, we provide a comprehensive overview of relationships between the levels of TGF-β in HM and allergic outcomes.

Although it was not possible to perform a meta-analysis, qualitative synthesis suggests that there is insufficient evidence of TGF-β influence on atopy/allergy development. Out of 15 studies only 3 found significant associations between TGF-β and eczema, 3 out of 14 with allergic sensitisation, 2 out of 9 with wheezing/asthma and none out of 5 linked TGF-β with IgE-mediated food allergy development. These results, however, do not completely exclude the possibility of TGF-β to impact allergic diseases development as a protective or negative effect was reported in some studies, with TGF-β1 being predominantly related to a protective effect and TGF-β2 associating with a higher risk of allergic disease.

Studies differed in methods applied and outcomes reported and in addition to methodological heterogeneity, most of the studies carried a high risk of bias, thus results should be interpreted with caution.

Across a limited number of studies suggesting associations between the levels of HM TGF-β and allergic outcomes, opposite effects are generally reported for TGF-β1 and TGF-β2 isoforms. TGF-β1 is mainly associated with the protective effect, while TGF-β2 is linked with a higher risk of atopy/allergy development. There is increasingly more evidence, suggesting that TGF-β acts as a bi-functional
regulator, with its context-dependent nature of activities confirmed in a variety of biological responses and cell systems. All TGF-β isoforms share a characteristic structure and are highly pleiotropic, but each isoform is linked with specific functions, therefore, may exert different effects. While TGF-β2 presents in much higher concentrations, accounting for up to 95% of TGF-β in HM, it is less potent than TGF-β1. TGF-β1-deficient mice were linked with the neonatal inflammatory disease, whereas TGF-β2,3-deficient mice present with developmental defects. This indicates that HM TGF-β isoforms may indeed have differential effects on allergy development.

HM contains a plethora of immune moderators, which may have synergistic and/or antagonistic effects to TGF-β, thus subsequently influencing the risk of atopy/allergy development. A recent study has investigated the effect of the immunological milieu of HM including 28 cytokines, chemokines and growth factors on development of cow’s milk allergy. The authors reported interactions between the immune markers and showed that networks of HM regulatory and pro-inflammatory cytokines including TGF-β1, IL-1β, IL-6 and IL-10 are associated with tolerance to cow’s milk development. These findings suggest that narrowing research to single components could result in conflicting and even misleading findings and suggests that HM studies should implement a more holistic approach given the links between development of the immune system and both the gut microbiome and HM oligosaccharides (HMO).

We found a high degree of heterogeneity between studies, with differences in methodology (sample collection, storage and processing), populations (general population and high risk), outcome definition, age at outcome assessment, and approaches to statistical analysis being the most important contributors. Lack of standardized protocols of HM sample collection, storage and processing is an important issue, influencing the quality of HM research, associated with heterogeneity and not allowing for quantitative synthesis.
Previous research linked a number of physiological and environmental factors with the changes of TGF-β levels in HM. Stage of lactation and time of sample collection, circadian and seasonal variations, time prior to freezing and length of sample storage, differences in laboratory techniques, ethnicity, residency, maternal lifestyle, smoking, diet, infection as well as depression and anxiety were found to be confounders and appear to impact TGF-β concentrations, thus possibly impacting health outcome development. Very few studies collected sufficient information and accounted for the duration and exclusivity of breastfeeding. Absence of this information prevents in-depth analysis of the dose-dependent effect. Although examination of associations between colostrum concentrations of HM components and infant outcomes is usually straightforward, the investigation of relationships with concentrations in mature HM is more problematic, given the variability in breastfeeding patterns and volumes of HM consumed during the lactation. Our systematic review highlights pitfalls in HM research, with results not being data adjusted for known confounding factors in many studies up to date with only a few using multivariate statistical analysis (Table SII).

Differences in statistical methods applied largely contributed to the results of this review, with a large variety of strategies employed, yet lacking comprehensive approach and consistency. The issues associated with carrying out multiple hypothesis tests were rarely considered leading to a high risk of false-positive results and missing data was common but not dealt with, possibly resulting in under- and/or over-estimation of association between the exposure and outcome. Adjustment for potentially important confounding factors may play an important part in identifying associations between levels of TGF-β and infant allergic outcomes but 6 studies did not report any adjustment. With heterogeneity in sample collection and processing, another important factor making meta-analysis impossible was data reporting, with some presenting adjusted and others non-adjusted data. In some studies data was not reported,
particularly if associations were not found to be significant. The different designs of the studies, e.g.
observational and interventional, make it difficult to compare the results, as potential influence of the
intervention cannot be excluded.

Health outcome definitions significantly varied between the studies contributing to heterogeneity. Some
studies used less reliable measurements such as infant itchy rash\textsuperscript{35}, scratching\textsuperscript{24} or asthma-like symptoms\textsuperscript{25}. Parental-reported allergic outcomes are not always accurate and the possibility of overdiagnosis cannot
be ruled out. It has been previously shown that mothers tend to over-report eczema in their children\textsuperscript{63}. It
should be noted, however, that most of the studies verified parental reports by physician assessment or
used well-validated tools, such as the ISAAC questionnaire\textsuperscript{64} or eczema UK Working party criteria\textsuperscript{65}.

There is also a marked difference in the age of health outcome assessment across the studies, ranging
between 6 months and 6 years of age. Thirty percent of individual health outcomes assessed in children
below 2 years of age were associated with TGF-β in HM, while only 3 out of 30 health outcomes at 2
years of age and beyond were found to be linked with TGF-β levels. This makes impact of HM TGF-β on
allergic outcomes improbable and even if it exists in selected populations, it is highly unlikely that it
extends beyond 2 years of age.

Atopic march theory suggests that allergic diseases progress from inflammatory skin manifestations, such
as eczema during infancy, to asthma and allergic rhinitis in later childhood\textsuperscript{66}. It has been demonstrated
that many “early wheezers” do not subsequently develop persistent asthma\textsuperscript{42}. There may even be an
inverse relationship between early infection-induced wheeze and subsequent asthma\textsuperscript{67}. It should be noted
that most of the studies assessing asthma included in this systematic review, were realistically measuring
wheeze rather than asthma, as age at health outcome assessment does not allow for appropriate asthma
diagnosis. Apart from the Orivuori et al. diagnosing asthma at 6 years of life\textsuperscript{37}, no other study measured
this health outcome beyond the age of 4 years. Considering lack of studies reporting doctor’s diagnosed health outcomes there is a need in further prospective cohorts, using well-validated instruments and standardized definitions, assessments of allergic outcomes and a considerable follow-up to evaluate the persistency of allergic symptoms.

The most recent systematic review \textsuperscript{19} provided an overall measure of the effect of HM TGF-\(\beta\) on immunological outcomes in infants and children and reported that 8 out of 12 studies showed a positive association between either TGF-\(\beta\)1 or TGF-\(\beta\)2 concentrations and a reduction in allergy-related outcomes. These results are in conflict with our findings, which may be explained by the difference in systematic review inclusion criteria. Oddy and Rosales reviewed all the studies reporting any immunological, biochemical and/or clinical outcomes, including those assessing associations between maternal allergic status and HM TGF-\(\beta\) concentration, while this paper reviews associations between HM TGF-\(\beta\) and atopy/allergy development in offspring only.

\textbf{Conclusion}

TGF-\(\beta\) is an important immunological factor involved in inflammation regulation. Biological effects of HM TGF-\(\beta\) on allergic outcomes during infancy and childhood need to be further elucidated. Although several associations have been observed between HM TGF-\(\beta\) and allergic outcomes, our updated systematic review did not find strong evidence of association between the levels of TGF-\(\beta\) in HM and atopy/allergy development. Studies would benefit from an investigation into any dose-dependent effect, with an apparent lack of studies measuring exact amounts of breast milk consumed, in addition to immuno-active molecules measurement. Future studies should employ standardised, validated methods, accurate phenotyping of outcomes, use of comprehensive and consistent statistical methods to enable
meta-analyses. Implementation of a more holistic approach, assessing multiple immune markers level, HMO and microbiome would improve the quality of the research in the field.

Acknowledgements

All authors critically reviewed and approved the final manuscript.

References


TABLE S1. Search strategies.

Embase Classic+Embase <1947 to 2017 June 7> (via Ovid)

1 allergy/ or hypersensitivity/ or immunoglobulin/ or immunoglobulin a/ or immunoglobulin a1/ or immunoglobulin a2/ or immunoglobulin e/ or secretory immunoglobulin/

2 (allergy or allergic diseases or allerg* or immun* outcomes or eczema or atopic dermatitis or itchy rash or allergic rhinitis or hay fever or food allergy or food hypersensitivity or asthma or wheeze or respiratory hypersensitivity or eosinophilic esophagitis or Ig serum level or immunoglobulin blood level or immunoglobulin level or immunoglobulin serum level or plasma immunoglobulin or serum gammaglobulin or serum immune globulin or IgA or IgA1 or IgA2 or immunoglobulin A or IgE or immunoglobulin E or secretory immunoglobulin).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word]

3 food allergy/ or hypersensitivity/

4 asthma/ or allergic asthma/

5 wheezing/

6 eczema/ or dermatitis/

7 1 or 2 or 3 or 4 or 5 or 6

8 transforming growth factor/ or transforming growth factor beta/

9 (Transforming growth factor beta or transforming growth factor beta1 or transforming growth factor beta2 or transforming growth factor beta3 or TGF beta or TGFbeta or TGF-beta or TGF*).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word]

10 8 or 9

11 colostrum/

12 human milk.mp. or breast milk/

13 (breast milk or breast milks or human milk or milk or breast milk human or mature milk or colostrum or early milk or transitional milk).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word]

14 11 or 12 or 13

15 (child* or infant* or boy* or girl* or newborn*).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word] (3306386)
1. “allergy” or allergic diseases or allerg* or immun* outcomes or “eczema” or “atopic dermatitis” or itchy rash or “allergic rhinitis” or “hay fever” or “food allergy” or food hypersensitivity or “asthma” or “wheeze” or respiratory hypersensitivity or eosinophilic esophagitis or Ig serum level or immunoglobulin blood level or “immunoglobulin” or immunoglobulin level or immunoglobulin serum level or plasma immunoglobulin or serum gammaglobulin or serum immune globulin or “IgA” or IgA1 or IgA2 or “immunoglobulin A” or “IgE” or “immunoglobulin E”

2. “Transforming growth factor beta” or “transforming growth factor beta 1” or “transforming growth factor beta 1 level” or “transforming growth factor beta1” or “transforming growth factor beta 2” or “transforming growth factor beta 3” or TGF beta or TGFbeta or TGF-beta or TGF*

3. “breast milk” or breast milks or human milk or milk or breast milk human or colostrum* or “colostrum” or mature milk or transitional milk

4. child* or “child” or infant* or “infant” or boy* or girl* or newborn* or “newborn”

5. #1 and #2 and #3 and #4

Cochrane library

Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) <1946 to Present>

1 hypersensitivity/ or conjunctivitis, allergic/ or dermatitis, atopic/ or eosinophilic esophagitis/ or food hypersensitivity/ or respiratory hypersensitivity/ or asthma/ or rhinitis, allergic/ or urticaria/ or immunoglobulins/ or serum globulins/ or Immunoglobulin E/ or blood immunoglobulins.mp. or immunoglobulin a.mp. or Immunoglobulin A/

2 (allergy or allergic diseases or allerg* or immun* outcomes or eczema or atopic dermatitis or itchy rash or allergic rhinitis or hay fever or food allergy or food hypersensitivity or asthma or wheeze or respiratory hypersensitivity or eosinophilic esophagitis or Ig serum level or immunoglobulin blood level or immunoglobulin level or immunoglobulin serum level or plasma immunoglobulin or serum gammaglobulin or serum immune globulin or IgA or IgA1 or IgA2 or immunoglobulin A or IgE or immunoglobulin E).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]

3 1 or 2
4 transforming growth factor beta/ or transforming growth factor beta1/ or transforming growth factor beta2/ or transforming growth factor beta3/

5 (Transforming growth factor beta or transforming growth factor beta1 or transforming growth factor beta2 or transforming growth factor beta3 or TGF beta or TGFbeta or TGF-beta or TGF*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]

6 4 or 5

7 Milk, Human/ or Colostrum.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]

8 (breast milk or breast milks or human milk or milk or breast milk human or colostrum* or mature milk or transitional milk).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, word, unique identifier, synonyms]

9 7 or 8

10 adolescent/ or child/ or child, preschool/ or infant/ or infant, newborn/ or infant, low birth weight/ or infant, postmature/ or infant, premature/

11 (child* or infant* or boy* or girl* or newborn*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]

12 10 or 11

13 3 and 6 and 9 and 12
<table>
<thead>
<tr>
<th>Study</th>
<th>Statistical analyses of association between groups and between TGF-β in HM and allergic outcomes</th>
<th>Data expression and outcomes reported</th>
<th>Data transformation and adjustment to potential confounders</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Interventional studies</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rautava 2002 31</td>
<td>The Student t-test for comparison of values between groups for normally distributed data. Mann-Whitney U-test for comparisons between groups for data of skewed distribution. The Chi-squared test for comparisons of proportions between groups.</td>
<td>Mean (95%CI) Median (IQR)</td>
<td>NR</td>
</tr>
<tr>
<td>Bottcher 2008 10</td>
<td>Mann-Whitney U-test for unpaired analyses. Spearman's rank order correlation coefficient test for correlations analyses. Multiple logistic regression and ANOVA for analyses of multivariate relationships.</td>
<td>Mean (range) OR (95% CI) r</td>
<td>Study treatment (placebo or L. reuteri) Maternal atopy Na/K ratios</td>
</tr>
<tr>
<td>Hhuurre 2008 29</td>
<td>Mann-Whitney U-test, w2 test, the t-test for the baseline and clinical characteristics. The association between infant sensitization and TGF-β tertiles (T1, T2 and T3) was given descriptively.</td>
<td>GM (95% CI) Probiotic/placebo ratios (95% CI)</td>
<td>* Logarithmically transformed NR</td>
</tr>
<tr>
<td>Prescott 2008 30</td>
<td>Mann-Whitney test for differences between the groups for non-parametric data. Chi-square or Fisher’s exact test for differences between the groups for dichotomous data. Spearman or Kendall’s Tau for correlations.</td>
<td>Median (IQR) τ</td>
<td>Factors with potential confounding effects were tested by correlation analyses. NR</td>
</tr>
<tr>
<td>Kuitunen 2012 12</td>
<td>Mantel-Haenszel method for the association between HM variables and allergic outcomes by the ages of 2 and 5 years in the treatment groups separately. The Breslow-Day test for evaluation whether the association is different in the probiotic group from that of the placebo group.</td>
<td>GM (95% CI) OR (95% CI)</td>
<td>* Logarithmically transformed Assessed separately by treatment group if Breslow-Day test indicated interaction</td>
</tr>
<tr>
<td>Ismail 2013 11</td>
<td>The Student’s t-test for normally distributed continuous data. Mann-Whitney U-test was for skewed data. Chi-squared test or Fisher’s exact test for categorical data. Logistic regression analyses.</td>
<td>Mean (SEM) GM (95% CI) Median (IQR)</td>
<td>* Skewed data log10-transformed Treatment group Maternal allergic status</td>
</tr>
<tr>
<td>Simpson 2016 13</td>
<td>Wilcoxon matched-pairs signed-rank test for comparison of the concentration at 10 days and 3 months. Linear regression for effect of probiotic supplementation on TGF-β concentrations. Causal mediation analysis (paramed) for HM cytokines which were found to be altered by probiotic supplementation.</td>
<td>Median (IQR) RR</td>
<td>Maternal atopy Maternal smoking during the first year of life Presence of older siblings</td>
</tr>
<tr>
<td><strong>Observational studies</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kalliomaki 1999 6</td>
<td>The Fisher exact test or chi-squared test for differences in contingency tables. The Kruskal-Wallis test for comparisons between the groups. The Mann-Whitney U-test and Wilcoxon signed-rank test for comparisons between 2 unpaired and paired groups, respectively. Spearman rank correlation for correlation between 2 variables.</td>
<td>Median (IQR) % r</td>
<td>NR</td>
</tr>
<tr>
<td>Saarinen 1999 39</td>
<td>ANOVA was used for multiple comparisons. 2-tailed Student’s t-test for comparisons between groups. Spearman rank correlation test for correlations between measurement from colostrum samples and from infants with CMA.</td>
<td>Mean (95%CI) r</td>
<td>* Logarithmically transformed Maternal atopy tested, NS</td>
</tr>
<tr>
<td>Reference</td>
<td>Methodology</td>
<td>Description</td>
<td></td>
</tr>
<tr>
<td>-----------</td>
<td>-------------</td>
<td>-------------</td>
<td></td>
</tr>
<tr>
<td>Bottcher 2003</td>
<td>Mann-Whitney U-test rank test for groups comparison. Spearman’s rank order correlation coefficient test for correlations. The chi-square test for categorical variables, and Fisher’s exact test for when the expected frequency for any cell was less than 5.</td>
<td>Median, Frequency (%) in groups</td>
<td>NR</td>
</tr>
<tr>
<td>Oddy 2003</td>
<td>Spearman nonparametric tests for correlation coefficients between cytokines. Contingency tables and the chi-square test for relationship between breastfeeding and wheeze in the first year of life. The relationship of the concentration of each cytokine in milk to wheeze was assessed by dividing the concentrations into tertiles with trend chi-square tests. Logistic regression analyses to determine the odds for any wheeze associated with cytokine dose in milk. A final categorization of concentration and duration of breastfeeding was calculated to reflect short or long duration of feeding (divided in the median in weeks) and low vs. medium-high cytokine concentration.</td>
<td>Mean (95%CI) OR (95%CI)</td>
<td>Maternal characteristics: smoking at 1 year (any vs. none), education (≤12 vs. &gt;12 years), history of physician-diagnosed asthma (yes vs. no) Offspring characteristics: sex, gestational age (&lt;37 vs. ≥37 weeks), birth weight (≤6 lbs vs. &gt;6 lbs), exposure to other children (presence of any older siblings or attendance at daycare with other children before 3 months)</td>
</tr>
<tr>
<td>Savilahti 2005</td>
<td>Multivariate stepwise logistic regression analysis by the forward selection method. Associations with symptoms of atopy and verified atopy were studied among the whole study group, those with long or short breast-feeding, and those with or without family history for atopy.</td>
<td>GM (95%CI) OR (95%CI)</td>
<td>* Logarithmically transformed NR</td>
</tr>
<tr>
<td>Rigotti 2006</td>
<td>Independent samples t-test for normally distributed variables and the Mann-Whitney U-test for variables not normally distributed for the differences between two unpaired groups.</td>
<td>Median (range)</td>
<td>The two groups of mothers were comparable for aging, alimentary habits, and pregnancy course. NR</td>
</tr>
<tr>
<td>Snijders 2006</td>
<td>ANOVA for comparisons of concentrations between groups. Logistic regression analysis for association between cytokines and infant’s atopic manifestations. Extreme values of concentrations of cytokines were not excluded as these did not influence the results.</td>
<td>Mean (SD) OR (95%CI)</td>
<td>Recruitment group (conventional vs. alternative) Time interval between birth and HM collection (days) Total storage time in freezer until analysis (days) Maternal characteristics: age, allergic history, season of breast milk collection, use of probiotics, infection (during week of HM collection) Offspring characteristics: number of older siblings</td>
</tr>
<tr>
<td>Tomicic 2010</td>
<td>Mann-Whitney U test for unpaired analyses. Spearman’s rank-order correlation coefficient test for correlation analyses. The 2-test for categorical variables, and the Fisher’s exact test for when the expected frequency for any cell was 5.</td>
<td>Median (range) (\rho)</td>
<td>NR</td>
</tr>
<tr>
<td>Soto-Ramirez 2012</td>
<td>Intra-class and Spearman correlation for associations of serum and whey immune markers. Log-linear regression for associations between immune markers and asthma-like symptoms at age 6 months and ever asthma-like symptoms in the first year of life (supplemental material). GEE was applied to predict repeated occurrence of asthma-like symptoms in infants at ages 6 and 12 months. In addition, models excluding infants who had both wheezy bronchitis and asthma-like symptoms were also ran.</td>
<td>RR (95%CI)</td>
<td>Maternal characteristics: race, age at pregnancy, smoking during pregnancy, household cigarette use at ages 6 and 12 months, maternal history of asthma, eczema, rhinitis, consumption of antibiotics during pregnancy, vaginal infections/pelvic conditions during pregnancy Offspring characteristics: gender, any respiratory infections at ages 6 and 12 months, season of birth ** FDR adjustment</td>
</tr>
<tr>
<td>Joseph 2014</td>
<td>Chi-square tests for subgroup comparisons of participant characteristics for binary and categorical variables. Wilcoxon Rank Sum (WRS) test cytokine levels comparison. Student’s t-tests for comparison of continuous variables. Logistic regression model for each atopic phenotype with the log-transformed TGF(\beta)1 values and the variable of interest (infant race/ethnicity or maternal atopy), along with the interaction term.</td>
<td>GM (95%CI) OR (95%CI)</td>
<td>* Logarithmically transformed Maternal characteristics: atopic status Offspring characteristics: race/ethnicity</td>
</tr>
<tr>
<td>Reference</td>
<td>Methodology and Analysis Details</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------</td>
<td>----------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Orivuori 2014 37</td>
<td>Linear regression for association between levels of HM TGF-β1 and exposures occurring up to month 2 of age. Uni-/multivariate smoothed plots based on generalized additive regression modelling for graphical display of significant associations of dose variables and health outcomes.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jepsen 2016 33</td>
<td>Cox regression for the association between cytokine levels with age at onset of eczema and recurrent wheeze during the first 3 years of life. Principal component analysis (PCA) was used to decompose the complex data set into fewer dimensions, reflecting the immunological intermediary correlation structure, and to extract patterns that describe the predominant variations in HM immune mediator levels. To avoid the effect of reverse causality, a sensitivity analysis was performed excluding all children with eczema diagnosis before end of exclusive breastfeeding.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Soto-Ramirez 2016 24</td>
<td>Ordinal logistic regression for the effect of probiotics. Wilcoxon matched-pairs signed-rank test for comparison of concentrations at 2 time points. Linear regression for effect of probiotic supplementation on TGF-β concentrations. Causal mediation analysis (paramed) for breast milk cytokines which were found to be altered by probiotic supplementation. GEE adjusting for within-participant effects using the regular maximum likelihood method for determination of the role of TGF-β in scratching at ages 6 and 12 months.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Munblit 2017 35</td>
<td>Univariate analysis and correlation matrix, followed by multivariate analysis which included modelling, using least absolute shrinkage and selection operator (LASSO) and generalized linear model (GLM).</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Notes:**
- GM (95% CI) Quintiles
- HR (95% CI)
- Median (IQR)
- OR (95% CI)
- RR (95% CI)
- Logarithmically transformed
- * Logarithmically transformed
- Delivery mode
- Household income
- Maternal eczema history
- Filaggrin mutation
- Household dog at birth and exclusive breastfeeding length
- ** FDR adjustment
- OR, odds ratio; PCA, principal component analysis; RR, relative risk; SD, standard deviation; SEM, standard error of the mean; TGF-β, transforming growth factor beta; WRS, Wilcoxon Rank Sum.
# TABLE SIII. Associations between TGF-β in human milk and allergic outcomes in children

<table>
<thead>
<tr>
<th>Reference</th>
<th>Age at outcome assessment</th>
<th>TGF-β isoform and time of collection</th>
<th>Associations between human milk TGF-β and allergic outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Eczema (interventional studies)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rautava 2002</td>
<td>2 y.o</td>
<td>TGF-β1,2 (MM) 3 mo</td>
<td>NS (data not shown)</td>
</tr>
<tr>
<td>Bottcher 2008</td>
<td>2 y.o</td>
<td>TGF-β1,2 (C) 3d</td>
<td>NS (data not shown)</td>
</tr>
<tr>
<td>Prescott 2008</td>
<td>2 y.o</td>
<td>TGF-β1 (C) 3-7d</td>
<td>NS (data not shown)</td>
</tr>
<tr>
<td>Kuitunen 2012</td>
<td>2 y.o</td>
<td>TGF-β2 (C) 0-3d</td>
<td>↑TGF-β2 (MM) - ↑higher risk of E by the age of 2 years (OR, 2.30; 95% CI, 1.34-3.94)</td>
</tr>
<tr>
<td>Ismail 2013</td>
<td>1 y.o</td>
<td>TGF-β1 (TM) 7 d</td>
<td>No E (451.3 (330.4725.4)) vs. E (450.4 (357.2798.7)); NS, P = 0.7; aP = .9</td>
</tr>
<tr>
<td>Simpson 2016</td>
<td>2 y.o</td>
<td>TGF β1-3 (TM) 10 d</td>
<td>NS (data not shown)</td>
</tr>
<tr>
<td><strong>Eczema (observational studies)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kalliomaki 1999</td>
<td>1 y.o</td>
<td>TGF-β1,2 (C) 0d</td>
<td>↑TGF-β1 - ↑higher post-weaning onset of E compared with no onset (P = .0056) and pre-weaning onset (P = .0008); ↑TGF-β2 - ↑higher post-weaning onset of E compared with pre-weaning onset (P = .015) and comparable to nonatopic control subjects.</td>
</tr>
<tr>
<td>Savilahti 2005</td>
<td>4 y.o</td>
<td>TGF-β1,2 (MM) 3 mo</td>
<td>NS (data not shown)</td>
</tr>
<tr>
<td>Snijders 2006</td>
<td>1 y.o</td>
<td>TGF-β1 (MM) 1 mo</td>
<td>Low (2.0-166.9 pg/ml): aOR, 1.0; 95% CI, reference; n = 30 Middle (166.9-248.4 pg/ml): aOR, 1.14; 95% CI, 0.59-2.10; n = 32 High (248.5-1536.8): aOR, 1.00; 95% CI, 0.53-1.91; n = 28 P-value for trend: aOR, 1.00; 95% CI, n = 299</td>
</tr>
<tr>
<td>Rigotti 2006</td>
<td>6 mo</td>
<td>TGF-β1 (C) 3d</td>
<td>4/6 infants who developed E received milk with no TGF-β1 in both C and MM. No statistical analysis has been performed.</td>
</tr>
<tr>
<td>Tomicic 2010</td>
<td>2 y.o</td>
<td>TGF-β1,2 (C) 0-4 d</td>
<td>NS (data not shown)</td>
</tr>
<tr>
<td>Orivuori 2014</td>
<td>2 y.o</td>
<td>TGF-β1,2 (C) 1-4 d</td>
<td>NS: aOR, 0.86; 95% CI, 0.65-1.14. all NS (aOR, 95% CI): Q1, 1.00; Q2, 0.95, 0.48-1.90; Q3, 1.12, 0.58-2.16; Q4, 0.64, 0.30-1.34; Q5, 1.00, 0.50-1.98. NS: aOR, 0.83; 95% CI, 0.63-1.08. all NS (aOR, 95% CI): Q1, 1.00; Q2, 0.77, 0.40-1.51; Q3, 1.13, 0.60-2.12; Q4, 0.87, 0.45-1.71; Q5, 1.10, 0.57-2.09.</td>
</tr>
<tr>
<td>Jepsen 2016</td>
<td>3 y.o</td>
<td>TGF-β1 (MM) 1 mo</td>
<td>HR 0.89; 95% CI, 0.72-1.10; P = 0.29; aHR 0.91; 95% CI, 0.74-1.12</td>
</tr>
<tr>
<td>Soto-Ramirez 2016</td>
<td>Scratching 1 y.o</td>
<td>TGF-β1 (MM) 21d</td>
<td>NS: TGF-β1 level ≥774.63: RR, 0.71; 95 % CI, 0.48-1.05</td>
</tr>
<tr>
<td>Study</td>
<td>Age</td>
<td>TGF-β2 (C) 0-6 d</td>
<td>TGF-β2 (MM) 1 mo</td>
</tr>
<tr>
<td>----------------------------</td>
<td>-----</td>
<td>-----------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>Munblit 2017</td>
<td>6 mo.</td>
<td>TGF-β2 (C) 0-6 d</td>
<td>TGF-β2 (MM) 1 mo</td>
</tr>
<tr>
<td>Bottcher 2008</td>
<td>2 y.o.</td>
<td>TGF-β1,2 (MM) 3 mo</td>
<td>NS</td>
</tr>
<tr>
<td>Rautava 2002</td>
<td>2 y.o.</td>
<td>TGF-β1 (C) 3 d</td>
<td>TGF-β1 (C) &lt;701**</td>
</tr>
<tr>
<td>Snijders 2006</td>
<td>2 y.o.</td>
<td>TGF-β1 (C) 3-7 d</td>
<td>TGF-β1 (MM) 1 and 3 mo</td>
</tr>
<tr>
<td>Ismail 2013</td>
<td>1 y.o.</td>
<td>TGF-β1 (TM) 7 d</td>
<td>TGF-β1 (MM) 28 d</td>
</tr>
<tr>
<td>Simpson 2016</td>
<td>2 y.o.</td>
<td>TGF-β1-3 (TM) 10 d</td>
<td>TGF-β1-3 (MM) 3 mo</td>
</tr>
</tbody>
</table>

**Atopic sensitization (interventional studies)**

- **Munblit 2017**
  - 6 mo.
  - TGF-β2 (C) 0-6 d
  - TGF-β2 (MM) 1 mo
  - NS: $aP = 0.66$

**Atopic sensitization (observational studies)**

- **Saarinen 1999**
  - 1 y.o.
  - TGF-β1 (C) 1-4 d
  - $\uparrow$TGF-β1 (C) - $\uparrow$SPT to CM ($r = -0.228$, $P = .02$); $\downarrow$SI to α-casein ($r = -0.282$, $P = .04$) and $\downarrow$SI to β-lactoglobulin ($r = -.347$, $P = .01$);
  - NS: sIgE to CM ($r = -0.138$, $P = .017$); SI to β-casein ($r = -0.241$, $P = .08$).

- **Bottcher 2003**
  - 2 y.o.
  - TGF-β1,2 (C) 0-4 d
  - TGF-β1,2 (MM) 1 mo
  - NS (data not shown)

- **Savilahti 2005**
  - 4 y.o.
  - TGF-β1,2 (C) 1-4 d
  - NS (data not shown)

- **Snijders 2006**
  - 2 y.o.
  - TGF-β1 (MM) 1 mo
  - Low (2.0-166.9 pg/ml): aOR, 1.0; 95% CI, reference; $n = 17$.
  - Middle (166.9-248.4 pg/ml): aOR, 1.19; 95% CI, 0.52-2.74; $n = 21$.
  - High (248.5-1536.8 pg/ml): aOR, 0.51; 95% CI, 0.21-1.24; $n = 12$.
  - $P$-value for trend: aOR, 0.13; 95% CI, $n = 200$.

- **Tomicic 2010**
  - 2 y.o.
  - TGF-β1,2 (C) 0-4 d
  - NS: In Sweden (median, 486; range, 240-1400 pg/mL, in non-sensitized vs. median 586; range, 365-1156, in sensitized infants; $P = .11$).

- **Joseph 2014**
  - 3 y.o.
  - TGF-β1 (MM) 1 mo
  - $\downarrow$GM in non-atopic mothers of infants with elevated vs. not elevated sIgE (1347 vs. 1651 pg/ml respectively, $P = .047$)
  - $\uparrow$GM in atopic mothers of infants classified as allergen-specific IgE (2161 vs. 1525 pg/ml respectively, $P = .001$).

- **Orivuori 2014**
  - 4 y.o.
  - TGF-β1 (MM) 2 mo
  - NS: aOR, 1.10; 95% CI, 0.85-1.42.
  - Based on IgE cut-off 0.35KU/l:
    - All NS (aOR, 95% CI): Q1, 1.00; Q2, 1.10-2.01; Q3, 1.03, 0.56-1.91; Q4, 1.46, 0.79-2.70; Q5, 1.76, 0.93-3.32.
    - All other cut-offs/ages: NS, $P > .05$.

- **Munblit 2017**
  - 6 mo.
  - TGF-β1-3 (C) 0-6 d
  - TGF-β1-3 (MM) 1 mo
  - NS (data not shown)
### Asthma/wheezeing (observational studies)

<table>
<thead>
<tr>
<th>Study</th>
<th>Age</th>
<th>markers</th>
<th>Duration</th>
<th>Control</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oddy 2003</td>
<td>4 y.o</td>
<td>TGF-β1 (MM)</td>
<td>14 d</td>
<td>NS</td>
<td>OR, 1.04; 95% CI, 0.62-1.76</td>
</tr>
<tr>
<td></td>
<td>6 y.o</td>
<td>TGF-β2 (MM)</td>
<td>1 mo</td>
<td>NS</td>
<td>OR, 1.08; 95% CI, 0.66-1.77</td>
</tr>
<tr>
<td></td>
<td>5 y.o</td>
<td>TGF-β3 (MM)</td>
<td>1 mo</td>
<td>NS</td>
<td>OR, 1.13; 95% CI, 0.66-2.62</td>
</tr>
<tr>
<td></td>
<td>4 y.o</td>
<td>TGF-β1 (MM)</td>
<td>1 mo</td>
<td>NS</td>
<td>OR, 1.06; 95% CI, 0.63-1.79</td>
</tr>
<tr>
<td></td>
<td>3 y.o</td>
<td>TGF-β2 (MM)</td>
<td>1 mo</td>
<td>NS</td>
<td>OR, 1.08; 95% CI, 0.66-2.62</td>
</tr>
<tr>
<td></td>
<td>2 y.o</td>
<td>TGF-β3 (MM)</td>
<td>1 mo</td>
<td>NS</td>
<td>OR, 1.04; 95% CI, 0.62-1.73</td>
</tr>
<tr>
<td>Sotomo 2012</td>
<td>1 mo</td>
<td>TGF-β1</td>
<td>2 d</td>
<td>NS</td>
<td>OR, 1.31; 95% CI, 0.66-2.62</td>
</tr>
<tr>
<td>Snijders 2006</td>
<td>2 y.o</td>
<td>TGF-β1 (MM)</td>
<td>1 mo</td>
<td>NS</td>
<td>OR, 1.08; 95% CI, 0.66-1.77</td>
</tr>
<tr>
<td></td>
<td>6 y.o</td>
<td>TGF-β2 (MM)</td>
<td>1 mo</td>
<td>NS</td>
<td>OR, 1.73; 95% CI, 0.73-2.99</td>
</tr>
</tbody>
</table>

### Food allergy (observational studies)

<table>
<thead>
<tr>
<th>Study</th>
<th>Age</th>
<th>markers</th>
<th>Duration</th>
<th>Control</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph 2014</td>
<td>3 y.o</td>
<td>TGF-β1 (MM)</td>
<td>1 mo</td>
<td>NS</td>
<td>aOR, 0.92; 95% CI, 0.62-1.38</td>
</tr>
<tr>
<td></td>
<td>6 y.o</td>
<td>TGF-β2 (MM)</td>
<td>1 mo</td>
<td>NS</td>
<td>aOR, 0.90; 95% CI, 0.73</td>
</tr>
<tr>
<td></td>
<td>3 y.o</td>
<td>TGF-β3 (MM)</td>
<td>1 mo</td>
<td>NS</td>
<td>aOR, 0.91; 95% CI, 0.68-1.23</td>
</tr>
</tbody>
</table>

### Food allergy (interventional studies)

<table>
<thead>
<tr>
<th>Study</th>
<th>Age</th>
<th>markers</th>
<th>Duration</th>
<th>Control</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saarinen 1999</td>
<td>1 y.o</td>
<td>TGF-β1</td>
<td>1-4 d</td>
<td>NS</td>
<td>aOR, 0.57, 0.18-1.84</td>
</tr>
<tr>
<td></td>
<td>1 y.o</td>
<td>TGF-β2</td>
<td>1-4 d</td>
<td>NS</td>
<td>aOR, 0.43, 0.12-1.50</td>
</tr>
<tr>
<td></td>
<td>1 y.o</td>
<td>TGF-β3</td>
<td>1-4 d</td>
<td>NS</td>
<td>aOR, 0.53, 0.15-1.87</td>
</tr>
<tr>
<td></td>
<td>1 y.o</td>
<td>TGF-β4</td>
<td>1-4 d</td>
<td>NS</td>
<td>aOR, 0.65, 0.21-2.02</td>
</tr>
<tr>
<td></td>
<td>1 y.o</td>
<td>TGF-β5</td>
<td>1-4 d</td>
<td>NS</td>
<td>aOR, 0.92, 95% CI, 0.62-1.38</td>
</tr>
</tbody>
</table>

### Allergic rhinitis/conjunctivitis (observational studies)

<table>
<thead>
<tr>
<th>Study</th>
<th>Age</th>
<th>markers</th>
<th>Duration</th>
<th>Control</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kuittunen 2013</td>
<td>2 y.o</td>
<td>TGF-β2</td>
<td>0-3 d</td>
<td>NS</td>
<td>OR, 1.09; 95% CI, 0.62-1.76</td>
</tr>
<tr>
<td></td>
<td>2 y.o</td>
<td>TGF-β3</td>
<td>0-3 d</td>
<td>NS</td>
<td>OR, 1.08; 95% CI, 0.66-2.62</td>
</tr>
<tr>
<td></td>
<td>2 y.o</td>
<td>TGF-β4</td>
<td>0-3 d</td>
<td>NS</td>
<td>OR, 1.13; 95% CI, 0.66-2.62</td>
</tr>
<tr>
<td></td>
<td>2 y.o</td>
<td>TGF-β5</td>
<td>0-3 d</td>
<td>NS</td>
<td>OR, 1.06; 95% CI, 0.63-1.79</td>
</tr>
</tbody>
</table>

### Studies with combined allergic outcomes (observational studies)

<table>
<thead>
<tr>
<th>Study</th>
<th>Age</th>
<th>markers</th>
<th>Duration</th>
<th>Control</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bottcher 2003</td>
<td>2 y.o</td>
<td>TGF-β1,2</td>
<td>0-4 d</td>
<td>NS</td>
<td>OR, 1.05; 95% CI, 0.62-1.76</td>
</tr>
<tr>
<td></td>
<td>2 y.o</td>
<td>TGF-β2</td>
<td>1-4 d</td>
<td>NS</td>
<td>OR, 1.08; 95% CI, 0.66-2.62</td>
</tr>
<tr>
<td></td>
<td>2 y.o</td>
<td>TGF-β3</td>
<td>1-4 d</td>
<td>NS</td>
<td>OR, 1.13; 95% CI, 0.66-2.62</td>
</tr>
</tbody>
</table>

### Studies with combined allergic outcomes (interventional studies)

<table>
<thead>
<tr>
<th>Study</th>
<th>Age</th>
<th>markers</th>
<th>Duration</th>
<th>Control</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph 2014</td>
<td>3 y.o</td>
<td>TGF-β1</td>
<td>1 mo</td>
<td>NS</td>
<td>aOR, 0.92; 95% CI, 0.62-1.38</td>
</tr>
<tr>
<td></td>
<td>6 y.o</td>
<td>TGF-β2</td>
<td>1 mo</td>
<td>NS</td>
<td>aOR, 0.90; 95% CI, 0.73</td>
</tr>
<tr>
<td></td>
<td>3 y.o</td>
<td>TGF-β3</td>
<td>1 mo</td>
<td>NS</td>
<td>aOR, 0.91; 95% CI, 0.68-1.23</td>
</tr>
</tbody>
</table>

Note: OR = Odds Ratio, CI = Confidence Interval, NS = Not Significant.
A 2 y.o TGF-β1,2 (MM) 1 mo NS: the number of positive samples or the levels of the cytokines in C or MM and the development of either allergic symptom (P-values: .14 - .99).

A, asthma; AlD, allergic diseases; AtD, ‘atopic’ diseases; aHR, adjusted hazard ratio; aOR, adjusted odds ratio; aP, adjusted P-value; AR, allergic rhinitis; ARC, allergic rhinoconjunctivitis; AS, allergic sensitization; C, colostrum (0-4 days); CI, confidence interval; CM, cow’s milk; CMA, cow’s milk allergy; D, days; DNS, data not shown (not presented in the paper); E, eczema; FA, food allergy; FDR, false discovery rate (adjusted); GM, geometric mean; HR, hazard ratio; IQR, inter-quartile range; MA, multivariate analysis; MM, mature human milk (2 weeks and later); MO, months; NA, non-applicable; NR, not reported; NS, non-significant; OR, odds ratio; Q, quintile; RR, relative risk; SD, standard deviation; SI, stimulation index – expression of proliferation (median counts per minute incorporated in the presence of the antigen divided by median counts per minute incorporated in the absence of the antigen); SPT, skin prick test; sIgE, specific IgE levels; TGF-β, transforming growth factor beta; TM, transitional milk (5-14 days); W, wheezing. “↑” – stands for increased and “↓” – stands for decreased levels or reduced risk of TGF-β or disease/parameter; * Age, up to which outcomes were assessed; ** All concentrations are pg/ml; *** This study analyzed eczema separately and also combined allergic diseases for the analysis (eczema, food allergy, allergic rhinitis and asthma) and atopic (IgE-associated) allergic diseases.